Trial Profile
Phase II trial of dose dense neo-adjuvant gemcitabine, epirubicin, ABI-007 [paclitaxel] (GEA) in locally advanced or inflammatory breast cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Nov 2021
Price :
$35
*
At a glance
- Drugs Epirubicin (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary) ; Pegfilgrastim (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 02 May 2011 Celgene Corporation as company and lead trial centre added as reported by ClinicalTrials.gov.
- 23 Jun 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
- 23 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.